At the beginning of the month, Lilly CEO David Ricks told Bloomberg that he expected the shortage to end very soon, adding that actually today or tomorrow we plan to exit that process. On a recent earnings call, Lilly announced that seven sites are expected to help alleviate the supply issues
In part, the paucity of evidence on this topic is related to the lack of rich clinical data on a broad range of patients with enough long-term data following use of these medications for indications such as obesity
The connection between semaglutide and allodynia is complicated, and that complexity matters
Effect of GLP-1 receptor agonism on anthracycline- and HER2-targeted therapy-induced cardiac dysfunction and systemic inflammation in non-diabetic preclinical models
Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of kidney outcomes: emulation of a target trial using health care databases